ArriVent BioPharma Advances Cancer Therapeutics Pipeline

TipRanksNov 18, 2024 23:03 ET

H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsNov 15, 2024 06:34 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target

BenzingaNov 15, 2024 06:26 ET

ArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy Rating

TipRanksNov 15, 2024 06:05 ET · Ratings

Express News | Hhlr Advisors, Ltd. Reports Passive Stake of 13.4% in Arrivent Biopharma Inc as of September 30, 2024- SEC Filing

ReutersNov 14, 2024 17:14 ET

ArriVent Biopharma Reports Q3 EPS (61c), Consensus ($1.07)

TipRanksNov 14, 2024 08:13 ET